Long-acting capsid inhibitor protects macaques from repeat SHIV challenges.
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
02
06
2021
accepted:
24
11
2021
pubmed:
8
12
2021
medline:
15
4
2022
entrez:
7
12
2021
Statut:
ppublish
Résumé
Because no currently available vaccine can prevent HIV infection, pre-exposure prophylaxis (PrEP) with antiretrovirals (ARVs) is an important tool for combating the HIV pandemic
Identifiants
pubmed: 34875675
doi: 10.1038/s41586-021-04279-4
pii: 10.1038/s41586-021-04279-4
pmc: PMC8753592
doi:
Substances chimiques
Anti-Retroviral Agents
0
Capsid Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
612-616Subventions
Organisme : NIAID NIH HHS
ID : T32 AI007387
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2021. The Author(s).
Références
World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach, 2nd ed. (World Health Organization Press, 2016).
Fonner, V. A. et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS 30, 1973–1983 (2016).
doi: 10.1097/QAD.0000000000001145
Coelho, L. E., Torres, T. S., Veloso, V. G., Landovitz, R. J. & Grinsztejn, B. Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline. Lancet HIV 6, e788–e799 (2019).
doi: 10.1016/S2352-3018(19)30238-3
Yant, S. R. et al. A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model. Nat. Med. 25, 1377–1384 (2019).
doi: 10.1038/s41591-019-0560-x
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1204–1222 (2020).
Abdool Karim, Q. et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168–1174 (2010).
doi: 10.1126/science.1193748
Grant, R. M. et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363, 2587–2599 (2010).
doi: 10.1056/NEJMoa1011205
Baeten, J. M. et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367, 399–410 (2012).
doi: 10.1056/NEJMoa1108524
Grulich, A. E. et al. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV 5, e629–e637 (2018).
doi: 10.1016/S2352-3018(18)30215-7
Sullivan, P. S. et al. The impact of pre-exposure prophylaxis with FTC/TDF on HIV diagnoses, 2012–2016. Presented at the 22nd International AIDS Conference, Amsterdam, the Netherlands, 23–27 July 2018 (2018).
Anderson, P. L. et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci. Transl. Med. 4, 151ra125 (2012).
doi: 10.1126/scitranslmed.3004006
Van Damme, L. et al. Preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 367, 411–422 (2012).
doi: 10.1056/NEJMoa1202614
Marrazzo, J. M. et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 372, 509–518 (2015).
doi: 10.1056/NEJMoa1402269
Landovitz, R. J. et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N. Engl. J. Med. 385, 595–608 (2021).
doi: 10.1056/NEJMoa2101016
Carnes, S. K., Sheehan, J. H. & Aiken, C. Inhibitors of the HIV-1 capsid, a target of opportunity. Curr. Opin. HIV AIDS 13, 359–365 (2018).
doi: 10.1097/COH.0000000000000472
Link, J. O. et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature 584, 614–618 (2020).
doi: 10.1038/s41586-020-2443-1
Daar, E. et al. Dose–response relationship of subcutaneous long-acting HIV capsid inhibitor GS-6207. Presented at the 27th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 8–11 March 2020 (2020).
Begley, R. et al. Lenacapavir sustained delivery formulation supports 6-month dosing interval. Presented at AIDS 2020: 23rd International AIDS Conference, virtual, 6–10 July 2020 (2020).
Andrews, C. D. et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science 343, 1151–1154 (2014).
doi: 10.1126/science.1248707
Marzinke, M. A. et al. Characterization of HIV infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083. J. Infect. Dis. https://doi.org/10.1093/infdis/jiab152 (2021).
Margot, N. et al. Lenacapavir resistance analysis in a phase 1b clinical proof-of-concept study. Paper presented at 2020 HIV Drug Therapy Glasgow, virtual, 5–8 October 2020 (2020).
Ramanathan, R. et al. It is time for a paradigm shift in drug discovery bioanalysis: from SRM to HRMS. J. Mass Spectrom. 46, 595–601 (2011).
doi: 10.1002/jms.1921
Sturm, R. M., Jones, B. R., Mulvana, D. E. & Lowes, S. HRMS using a Q-Exactive series mass spectrometer for regulated quantitative bioanalysis: how, when, and why to implement. Bioanalysis 8, 1709–1721 (2016).
doi: 10.4155/bio-2016-0079